drugset / Trial / NCT07629167
Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
Phase 2
Not yet recruiting
50 enrolled
University of California, San Francisco
Day One Biopharmaceuticals, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.
Timeline
- Start
- 2026-08-30
- Primary completion
- 2029-08-30
- Completion
- 2030-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 50 mg | Oral |
| Subject | Doxycycline | Small molecule | 100 mg | Oral |
| Subject | Isotretinoin | Other / unclassified | 10 mg | Oral |
| Subject | Isotretinoin | Other / unclassified | 40 mg | Oral |